SAN FRANCISCO--(BUSINESS WIRE)--Great Basin Corporation, a privately-held molecular diagnostics company developing sample-to-result solutions, today presented initial data of its Candida assay during the Clinical Mycology—Diagnosis, Treatment and Epidemiology (Division F) session at the American Society of Microbiology General Meeting in San Francisco. Currently under development, the assay can detect the most medically relevant Candida species within an hour from blood cultures taken from patients with fungal bloodstream infections (BSI), speeding diagnosis and appropriate treatment for better patient outcomes.
